Publications by authors named "Raquel Ona"

Claim this Profile
I
Insights into the clinical, platelet and genetic landscape of inherited thrombocytopenia with malignancy risk.
Ana Marín-Quílez, Ana Sánchez-Fuentes, Ana Zamora-Cánovas, Pedro Luis Gómez-González, Lorena Diaz-Ajenjo

Br J Haematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal hematopoiesis is common in bone marrow of patients with classical Hodgkin lymphoma.
Rebeca Iglesias, Eva Díaz, Sara Fernández, Marta Miguélez, María De Rosa Torres

Haematologica· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study.
Mariana Bastos-Oreiro, Antonio Gutierrez, Almudena Cabero, Javier López, Paola Villafuerte

Cancers (Basel)· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets.
Eva Gonzalez Barca, Laura Tomás-Roca, Anna Esteve, Marta Rodriguez, Lucía Gato, Rebeca Sanz-Pamplona

Am J Hematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Branched clonal evolution: nodal follicular lymphoma and primary diffuse large B-cell lymphoma of the central nervous system.
Gilberto I Barranco, Sara Fernández, Raquel Oña, Julia González-Rincón, Angel Martínez-Ramírez

Haematologica· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
Carlos Montalbán, Antonio Díaz-López, Alejandro Martín, Mónica Baile, José M Sanchez

Br J Haematol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β -microglobulin yields a more accurate GELTAMO-IPI.
Carlos Montalbán, Antonio Díaz-López, Ivan Dlouhy, Jordina Rovira, Armando Lopez-Guillermo

Br J Haematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Carlos Panizo, Anny Jaramillo Rodríguez, Gonzalo Gutiérrez, Francisco Javier Díaz, Eva González-Barca

Clin Lymphoma Myeloma Leuk· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term survival in a patient with progressive multifocal leukoencephalopathy after therapy with rituximab, fludarabine and cyclophosphamide for chronic lymphocytic leukemia.
Heidys Garrote, Adolfo de la Fuente, Raquel Oña, Inmaculada Rodríguez, Juan E Echevarría

Exp Hematol Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Blanca Sanchez-Gonzalez, F Javier Peñalver, Angeles Medina, Helga Guillén, Marta Calleja

Leuk Res· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.
Ana Rivero, Inmaculada Rapado, José F Tomás, Carlos Montalbán, Raquel de Oña

Leuk Res· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
José Francisco Tomás, Carlos Montalbán, Alberto Fernández De Sevilla, Joaquín Martínez-López, Nicolás Díaz

Leuk Lymphoma· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of thrombophylic states in myeloma patients receiving thalidomide: a reasonable doubt.
Ana Belén Santos, Pilar Llamas, Alejandro Román, Elena Prieto, Raquel De Oña

Br J Haematol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis